Selurampanel
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H19N5O4S |
| Molar mass | 377.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.[1][2][3] It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.[4]
References
[edit]- ^ Faught E (January 2014). "BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy". Expert Opinion on Investigational Drugs. 23 (1): 107–113. doi:10.1517/13543784.2014.848854. PMID 24147649. S2CID 40105670.
- ^ Belcastro V, Verrotti A (2015). "Novel Molecular Targets for Drug-Treatment of Epilepsy". In Striano P (ed.). Epilepsy Towards the Next Decade. Contemporary Clinical Neuroscience. pp. 183–199. doi:10.1007/978-3-319-12283-0_10. ISBN 978-3-319-12282-3.
- ^ Hanada T (2014). "The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence". Journal of Receptor, Ligand and Channel Research: 39. doi:10.2147/JRLCR.S51475. ISSN 1178-699X.
- ^ Gomez-Mancilla B, Brand R, Jürgens TP, Göbel H, Sommer C, Straube A, et al. (February 2014). "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks". Cephalalgia. 34 (2): 103–113. doi:10.1177/0333102413499648. PMID 23963355. S2CID 206520491.
 | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |